News
Sanofi Upbeat on Sales Outlook
Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...
Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...
FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...
Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
Among individual stocks, Italy's Campari was the top gainer on the STOXX 600 index, adding 8.6% after reporting an increase ...
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate ...
Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...
Shares of Regeneron Pharmaceuticals were rising Friday after the biopharmaceutical company’s revenue and earnings comfortably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results